Abu Dhabi [UAE], December 28 (ANI/WAM): The UAE's industry and advanced technology sector continues to achieve exceptional qualitative leaps, supported by a robust, sustainable infrastructure, flexible legislation, and a high-quality system of standards and technical regulations that enhance the competitiveness of Emirati products. The sector has strengthened its role in sustainable economic development, enhanced its competitiveness, and contributed to the country's GDP under the National Strategy for Industry and Advanced Technology "Operation 300bn." Also Read | Earthquake in UAE: Light Quake of Magnitude 2.2 on Richter Scale Hits Falaj Al Mualla. In statements to the Emirates News Agency (WAM), Omar Al Suwaidi, Under-Secretary of the Ministry of Industry and Advanced Technology, said that the Industrial sector's contribution to GDP rose to 11 percent, reaching AED205 billion by end of 2023. He noted that this progress has enhanced the sector's role in the country's economic diversification and support for sustainable development. This is confirmed by global competitiveness reports, which show the UAE's ranking rising from 35th place in 2019 to 27th globally and first in the Arab world, according to UNIDO's Competitive Industrial Performance Index (CIP). Also Read | Azerbaijan Airline Plane Crash: Russian President Vladimir Putin Apologises to Azerbaijan President Ilham Aliyev After Fatal Flight 8432 Crash. Al Suwaidi also noted that the National In-Country Value (ICV) Programme launched as part of "Projects of the 50", redirected over AED 73 billion in corporate spending into the national economy as of Q3 2024. This initiative has fostered growth and integration among industrial and service companies while creating social impact, with over 19,000 Emiratis employed in private sector companies certified by the programme. He stated that the Industrial Development Council comprising federal, local, and industrial zone representatives, has played a crucial role in streamlining industrial licensing procedures and implementing a new industrial law that eases licensing requirements, particularly for SMEs. Over the past few years, industrial financing has significantly expanded, with over AED 19 billion in competitive funding provided by the Emirates Development Bank and other financial institutions. In 2024, AED 9.5 billion in financing was allocated to the industrial sector, including AED 1.1 billion for advanced technology and AED 1.8 billion in credit solutions provided by Etihad Credit Insurance. The "Make it in the Emirates" Forum has achieved remarkable milestones across its three editions. By the end of 2023, purchase agreements for locally manufactured products over a 10-year period had reached AED143 billion, covering 2,000 locally produced items. Additionally, manufacturing contracts worth AED62 billion were awarded, and over 300 products were produced and purchased in quantities valued at approximately AED7 billion. (ANI/WAM) (This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)Charles attended the show at the Royal Albert Hall in London for the first time as patron of the Royal Variety charity, following in the footsteps of his mother, the late Queen Elizabeth II. In a statement from Buckingham Palace, he said: “The charity’s crucial work in assisting those who have fallen ill, had an accident or hit hard times is as essential now as it ever has been. “I would like to thank all of those who have worked so hard to stage this year’s production and wish everyone a very enjoyable evening.” The performance saw political comic Forde reference the unfounded claims Mr Trump repeated during his presidential debate against Democrat candidate Kamala Harris earlier this year, that illegal immigrants from Haiti were eating locals’ pets in the small Ohio city of Springfield. Forde exclaimed in the president-elect’s voice: “They’re eating the cats, they’re eating the dogs!” He then turned to address Charles from the stage, saying in Mr Trump’s voice: “Your Majesty King Charles, you’re named after a spaniel – be very careful, they’ll eat you alive.” The King was seen laughing in response to the joke from the royal box. Charles appeared at the event without the Queen, who insisted the “show must go on” after pulling out of attending the performance on Friday evening as doctors advised that she should prioritise rest. A Buckingham Palace spokesperson said: “Following a recent chest infection, the Queen continues to experience some lingering post-viral symptoms, as a result of which doctors have advised that, after a busy week of engagements, Her Majesty should prioritise sufficient rest. “With great regret, she has therefore withdrawn from attendance at tonight’s Royal Variety Performance. His Majesty will attend as planned.” A royal source said the Queen was “naturally disappointed to miss the evening’s entertainments and sends her sincere apologies to all those involved, but is a great believer that ‘the show must go on'”. “She hopes to be back to full strength and regular public duties very soon,” the source added. The Royal Variety Performance will air on ITV1, ITVX, STV and STV Player in December. Money raised from the show will go to help people from the world of entertainment in need of care and assistance, with the Royal Variety Charity launching an initiative to help those with mental health issues this year.Navigating hybrid futures: resilience in a connected age
BOSSCATTM Home Services and Technologies Wins IMN 2024 Contractor of the Year Award at Third Annual Industry Award Ceremony
TOKYO and CAMBRIDGE, Mass. , Dec. 4, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts , CEO: Christopher A. Viehbacher , "Biogen") announced today that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI ® " (lecanemab) for the treatment of early Alzheimer's disease (AD)*. LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils**), as well as insoluble Aβ aggregates (fibrils) which are a major component of Aβ plaques, thereby reducing both Aβ protofibrils and Aβ plaques in the brain. LEQEMBI is the first approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism. LEQEMBI is also approved and being marketed in the U.S., Japan , China , South Korea , Hong Kong , Israel , the United Arab Emirates, and Great Britain . LEQEMBI's approval is based on the large global Phase 3 Clarity AD study. In the Clarity AD study, LEQEMBI met its primary endpoint and all key secondary endpoints with statistically significant results. 1,2 Approximately 1.3 million people in Mexico are estimated to suffer from AD, accounting for 60-70% of all dementia diagnoses. 3 AD most commonly affects individuals over the age of 65. 3 Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. Eisai and Biogen will co-commercialize and co-promote LEQEMBI in Mexico . * Collectively referred to mild cognitive impairment due to AD or mild AD dementia. ** Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition. 4 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction. 5 Notes to Editors 1. About lecanemab (LEQEMBI ® ) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is approved and being marketed in the U.S., Japan , China , South Korea , Hong Kong , Israel , the United Arab Emirates and Great Britain for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). The treatment's approvals in these countries was based on Phase 3 data from Eisai's global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results. 1,2 The most common adverse events (>10%) in the lecanemab group were infusion reactions, ARIA-H (combined cerebral microhemorrhages, cerebral macrohemorrhages, and superficial siderosis), ARIA-E (edema/effusion), headache, and fall. Lecanemab is under regulatory review in 16 countries and regions, including the European Union. In November 2024 , the treatment received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval. Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022 , the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis , is ongoing and includes lecanemab as the backbone anti-amyloid therapy. 2. About the Collaboration between Eisai and Biogen for AD Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. 3. About the Collaboration between Eisai and BioArctic for AD Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007 . The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015 . 4. About Eisai Co., Ltd. Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care ( hhc ) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners. For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai. Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai, Inc.) or www.eisai.eu (for Europe , Middle East , Africa , Russia , Australia and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on X ( global and U.S ), LinkedIn (for global , U.S. and EMEA ) and Facebook ( global ). 5. About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. The company routinely posts information that may be important to investors on its website at www.biogen.com . Follow Biogen on social media – Facebook , LinkedIn , X , YouTube . Biogen Safe Harbor This news release contains forward-looking statements, about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation unexpected concerns that may arise from additional data, analysis or results obtained during clinical studies; the occurrence of adverse safety events; risks of unexpected costs or delays; the risk of other unexpected hurdles; regulatory submissions may take longer or be more difficult to complete than expected; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen's drug candidates, including lecanemab; actual timing and content of submissions to and decisions made by the regulatory authorities regarding lecanemab; uncertainty of success in the development and potential commercialization of lecanemab; failure to protect and enforce Biogen's data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; and third party collaboration risks, results of operations and financial condition. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen's expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements. References View original content to download multimedia: https://www.prnewswire.com/news-releases/leqembi-lecanemab-approved-for-the-treatment-of-early-alzheimers-disease-in-mexico-302322515.html SOURCE Eisai Inc.'Squopping and squidging': Who invented tiddlywinks?KOCHI: The Kochi CBI special court found 14 accused guilty in the gruesome Kasaragod Periya twin murder case, including CPM leaders Uduma former MLA KV Kunhiraman and Kanhangad block panchayat president K. Manikandan. Judge N. Seshadrinathan will pronounce the final verdict on January 3. In February 2019, Youth Congress workers Sarath Lal (23) and Kripesh (19), were stopped by assailants from their bikes and hacked to death. The CBI established that the purpose of the crime was to stymie the surging congress influence in the area. A. Peethambaran, Saji C. George, K.M. Suresh, K. Anilkumar (Abu), Jijin, R. Sreerag (Kuttu), A. Ashwin (Appu), and Subish (Mani) are the accused. T. Ranjith, the 10th accused, and A. Surendran (Vishnu Sura), the 15th accused, are involved in a conspiracy amounting to murder. The 14th accused K. Manikandan, the 20th accused former MLA KV Kunhiraman, the 21st accused Raghavan Velutholi and the 22nd accused Bhaskaran Velutholi are accused of forcibly releasing the second accused from custody. This offence is punishable with imprisonment of up to two years and a fine. Public Prosecutor Bobby Joseph appeared in the case. Former MLA K Kunhiraman is a member of CPM Kasaragod District Secretariat. K. Manikandan is the leader of DYFI. The first accused Peethambaran is a former member of the CPM Periya Local Committee. Raghavan Velutholi is a former Pakkam local secretary. The High Court handed over the investigation to the CBI, only after criticizing the crime branch investigation as unreliable and politically biased. A team headed by Deputy Superintendent T.P. Ananthakrishnan of the CBI Thiruvananthapuram unit investigated the case. “The CPM leaders were deliberately roped into the case. The party has nothing to do with it. An appeal will be filed in the Supreme Court” - M.V. Balakrishnan, CPM Kasaragod district secretary. “Not satisfied with the verdict. Legal action will be taken to punish the wrongdoers." PV Krishnan, (father of Kripesh)
Abortions are up in the US. It's a complicated picture as women turn to pills, travel
According to the India Meteorological Department. Mumbai is expected to experience overcast skies with a slight chance of rain, especially in the evening on December 5. In Delhi, clear skies with a cool breeze will dominate, with temperatures hovering around 15°C to 25°C. Chennai is likely to witness intermittent showers throughout the day, with temperatures ranging from 22°C to 30°C. Bengaluru will enjoy mild, pleasant weather with a high of 27°C, though light showers may occur in the late afternoon. Hyderabad will have mostly clear skies, with temperatures between 19°C and 29°C. In Kolkata, light rain is expected in the morning, followed by partly cloudy conditions, with temperatures between 20°C and 30°C. Mumbai Weather Forecast and Update Today: City to Get Few Rain Spells for Next 48 Hours, Slight Drizzle Expected in Thane and Palghar . (SocialLY brings you all the latest breaking news, viral trends and information from social media world, including Twitter, Instagram and Youtube. The above post is embeded directly from the user's social media account and LatestLY Staff may not have modified or edited the content body. The views and facts appearing in the social media post do not reflect the opinions of LatestLY, also LatestLY does not assume any responsibility or liability for the same.)Wall Street stocks declined on Wednesday, retreating from records after pricing data showed an uptick in inflation, as leading companies fell after earnings reports. After three straight closing records for the Dow and Tuesday's record for the S&P 500, both dropped along with the Nasdaq in the final full trading session of the week. The Dow Jones finished down 0.3 percent at 44,722. The S&P 500 fell 0.4 percent to 5,998, while the Nasdaq shed 0.6 percent to 19,060. Despite Wednesday's lacklustre session, investors are optimistic about the upcoming period. A note from CFRA Research pointed out that December has historically been the strongest month of the year for the S&P 500 since World War II. "We project additional new highs through year-end as the S&P approaches our 6,145 target level," CFRA said in the note. "However, the year ahead could offer additional challenges, which will likely lead to a below-average full-year gain." The personal consumption expenditures price index rose 2.3 percent in the 12 months to October, up from 2.1 percent in September, the Commerce Department announced. The benchmark is closely watched by the Federal Reserve. Futures markets currently place the odds at about two-thirds that the Fed will cut interest rates again in December by a quarter of a percentage point. Among individual companies, both Dell Technologies and HP Inc. fell sharply on disappointment with their profit outlooks. Dell slumped 12.3 percent and HP lost 11.4 percent. Department store Nordstrom also retreated, sinking 8.2 percent as it reported a 4.6 percent increase in revenues. But the company also reported lower profits in a move attributed to higher costs. Markets will be closed on Thursday and open for only a half-day on Friday. (AFP)Former Barcelona and Uruguay striker Luis Suarez has signed a one-year contract extension with the Major League Soccer club and will line up under new coach Javier Mascherano next season, the club said. The 37-year-old striker has scored 25 goals in all competitions since joining the club before the start of this season including 20 in Miami's record-breaking regular season campaign. After winning the Supporters' Shield for the best record in the regular season, with a new points tally record, Miami were eliminated from the playoffs in the first round by Atlanta United. Since then Argentina head coach Gerardo Martino has left the club with his compatriot and Suarez's former team-mate at Barca, Mascherano appointed on Tuesday. "I'm very happy, very excited to continue for another year and to be able to enjoy being here with this fan base, which for us is like family. We feel very, very connected with them, and hopefully, next year, we can bring them even more joy," said Suarez. Miami's president of football operations Raul Sanllehi said Suarez had shown he remains an elite level forward but was also a key component in the dressing room. "Luis was not only our leading scorer this season, but also a leader for the group. His impact cannot be understated," he said. Suarez announced in September he was retiring from international duty with the Uruguay national team after scoring 69 goals in 143 games. The forward played in Europe for Ajax, Liverpool and Atletico Madrid and had a season in Brazil with Gremio before joining Miami. sev/mw
NoneAs you scroll through your social media feed or let your favorite music app curate the perfect playlist, it may feel like artificial intelligence is improving your life – learning your preferences and serving your needs. But lurking behind this convenient facade is a growing concern: algorithmic harms. These harms aren’t obvious or immediate. They’re insidious, building over time as AI systems quietly make decisions about your life without you even knowing it. The hidden power of these systems is becoming a significant threat to privacy, equality, autonomy and safety. AI systems are embedded in nearly every facet of modern life. They suggest what shows and movies you should watch, help employers decide whom they want to hire, and even influence judges to decide who qualifies for a sentence. But what happens when these systems, often seen as neutral, begin making decisions that put certain groups at a disadvantage or, worse, cause real-world harm? The often-overlooked consequences of AI applications call for regulatory frameworks that can keep pace with this rapidly evolving technology. I study the intersection of law and technology, and I’ve outlined a legal framework to do just that. Slow burns One of the most striking aspects of algorithmic harms is that their cumulative impact often flies under the radar. These systems typically don’t directly assault your privacy or autonomy in ways you can easily perceive. They gather vast amounts of data about people — often without their knowledge — and use this data to shape decisions affecting people’s lives. Sometimes, this results in minor inconveniences, like an advertisement that follows you across websites. But as AI operates without addressing these repetitive harms, they can scale up, leading to significant cumulative damage across diverse groups of people. Consider the example of social media algorithms. They are ostensibly designed to promote beneficial social interactions. However, behind their seemingly beneficial facade, they silently track users’ clicks and compile profiles of their political beliefs, professional affiliations and personal lives. The data collected is used in systems that make consequential decisions — whether you are identified as a jaywalking pedestrian, considered for a job or flagged as a risk to commit suicide. Worse, their addictive design traps teenagers in cycles of overuse, leading to escalating mental health crises, including anxiety, depression and self-harm. By the time you grasp the full scope, it’s too late — your privacy has been breached, your opportunities shaped by biased algorithms, and the safety of the most vulnerable undermined, all without your knowledge. This is what I call “intangible, cumulative harm”: AI systems operate in the background, but their impacts can be devastating and invisible. Why regulation lags behind Despite these mounting dangers, legal frameworks worldwide have struggled to keep up. In the United States, a regulatory approach emphasizing innovation has made it difficult to impose strict standards on how these systems are used across multiple contexts. Courts and regulatory bodies are accustomed to dealing with concrete harms, like physical injury or economic loss, but algorithmic harms are often more subtle, cumulative and hard to detect. The regulations often fail to address the broader effects that AI systems can have over time. Social media algorithms, for example, can gradually erode users’ mental health, but because these harms build slowly, they are difficult to address within the confines of current legal standards. Four types of algorithmic harm Drawing on existing AI and data governance scholarship, I have categorized algorithmic harms into four legal areas: privacy, autonomy, equality and safety. Each of these domains is vulnerable to the subtle yet often unchecked power of AI systems. The first type of harm is eroding privacy. AI systems collect, process and transfer vast amounts of data, eroding people’s privacy in ways that may not be immediately obvious but have long-term implications. For example, facial recognition systems can track people in public and private spaces, effectively turning mass surveillance into the norm. The second type of harm is undermining autonomy. AI systems often subtly undermine your ability to make autonomous decisions by manipulating the information you see. Social media platforms use algorithms to show users content that maximizes a third party’s interests, subtly shaping opinions, decisions and behaviors across millions of users. The third type of harm is diminishing equality. AI systems, while designed to be neutral, often inherit the biases present in their data and algorithms. This reinforces societal inequalities over time. In one infamous case, a facial recognition system used by retail stores to detect shoplifters disproportionately misidentified women and people of color. The fourth type of harm is impairing safety. AI systems make decisions that affect people’s safety and well-being. When these systems fail, the consequences can be catastrophic. But even when they function as designed, they can still cause harm, such as social media algorithms’ cumulative effects on teenagers’ mental health. Because these cumulative harms often arise from AI applications protected by trade secret laws, victims have no way to detect or trace the harm. This creates a gap in accountability. When a biased hiring decision or a wrongful arrest is made due to an algorithm, how does the victim know? Without transparency, it’s nearly impossible to hold companies accountable. Closing the accountability gap Categorizing the types of algorithmic harms delineates the legal boundaries of AI regulation and presents possible legal reforms to bridge this accountability gap. Changes I believe would help include mandatory algorithmic impact assessments that require companies to document and address the immediate and cumulative harms of an AI application to privacy, autonomy, equality and safety – before and after it’s deployed. For instance, firms using facial recognition systems would need to evaluate these systems’ impacts throughout their life cycle. Another helpful change would be stronger individual rights around the use of AI systems, allowing people to opt out of harmful practices and making certain AI applications opt in. For example, requiring an opt-in regime for data processing by firms’ use of facial recognition systems and allowing users to opt out at any time. Lastly, I suggest requiring companies to disclose the use of AI technology and its anticipated harms. To illustrate, this may include notifying customers about the use of facial recognition systems and the anticipated harms across the domains outlined in the typology. As AI systems become more widely used in critical societal functions – from health care to education and employment – the need to regulate harms they can cause becomes more pressing. Without intervention, these invisible harms are likely to continue to accumulate, affecting nearly everyone and disproportionately hitting the most vulnerable. With generative AI multiplying and exacerbating AI harms, I believe it’s important for policymakers, courts, technology developers and civil society to recognize the legal harms of AI. This requires not just better laws, but a more thoughtful approach to cutting-edge AI technology – one that prioritizes civil rights and justice in the face of rapid technological advancement. The future of AI holds incredible promise, but without the right legal frameworks, it could also entrench inequality and erode the very civil rights it is, in many cases, designed to enhance. Sylvia Lu is a Faculty Fellow and Visiting Assistant Professor of Law, University of Michigan. The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.
NoneAP News Summary at 6:41 p.m. ESTKirk LaPointe: Surrey directors sound alarm over Metro Vancouver governance
Swampscott veterans worried about future of VFW building as town redevelops area
NEW YORK, N.Y., Dec. 17, 2024 (SEND2PRESS NEWSWIRE) — 4DDiG, a leading software solutions provider, and unit of Tenorshare, is spreading holiday cheer with the launch of its exciting 2024 Christmas Sale ! Starting December 12, 2024, customers can enjoy discounts of up to 80% on a wide selection of 4DDiG’s top-rated products, including PC and mobile data recovery software, AI-powered photo and video enhancer, disk management tool, and duplicate file remover. WHAT YOU CAN GET FROM THE 4DDIG CHRISTMAS SALE? Get Up to 80% Off This promotion includes all the tools you need, whether you’re looking to recover deleted photos from your SD card or try the latest AI video enhancer. Take advantage of the best discounts of the year: In 4DDiG Christmas Sale, the most worthwhile product to purchase is 4DDiG Data Recovery , which can recover lost data from over 2,000 types of storage devices. The best part of this software is that, compared to other alternatives, it offers the best data recovery experience at the most affordable price. Learn more: https://4ddig.tenorshare.com/special-offers.html https://4ddig.tenorshare.com/windows-data-recovery.html START AT $9.90 For a limited time, grab 4DDiG DLL Fixer and 4DDiG Disk Manager for only $9.90 – an offer you won’t find anywhere else this year. This offer is perfect for users who want to clone disks or migrate operating systems at the lowest cost. BUY 1 GET 1 FREE Buy 4DDiG Data Recovery and get a 4DDiG Duplicate File Deleter for free, or buy 4DDiG File Repair and receive the same amazing gift! Double the value for your purchase. WIN AMAZON SHOPPING CARD FOR FREE Follow 4DDiG on social media for a chance to win amazing prizes, including a $200 Amazon gift card! Here’s how you can participate: Step 1: Subscribe to any of 4DDiG’s official social media channels to unlock one entry into the lucky draw. You can earn up to five chances in total. Step 2: After that, click the “Start” button to spin the wheel and see if you’ve won a prize. About 4DDiG: 4DDiG is a software company with over ten years of experience, known for its advanced data recovery solutions. The company’s flagship product, 4DDiG Data Recovery, has been highly recognized by authoritative websites such as Make Use Of, PCWorld, and XDA-Developers. 4DDiG is now focusing on the development and application of AI technology. One of the company’s innovative AI-powered tools, 4DDiG File Repair, not only repairs damaged multimedia files but also colorize and enhance them. For more information about Tenorshare 4DDiG Christmas Sales, visit: https://4ddig.tenorshare.com/special-offers.html Social sites: Facebook: https://www.facebook.com/4DDiG/ Instagram: https://www.instagram.com/tenorshare_4ddig/ X/Twitter: https://x.com/Tenorshare4DDiG YouTube: https://www.youtube.com/@Tenorshare4DDiGDataRecovery/featured NEWS SOURCE: Tenorshare Co. Ltd. Keywords: Software, 4DDiG, Tenorshare, holiday sale, 4DDiG Data Recovery, File Repair, NEW YORK, N.Y. This press release was issued on behalf of the news source (Tenorshare Co. Ltd.) who is solely responsibile for its accuracy, by Send2Press® Newswire . Information is believed accurate but not guaranteed. Story ID: S2P122917 APDF15TBLLI To view the original version, visit: https://www.send2press.com/wire/4ddig-christmas-sale-2024-enjoy-up-to-80-off-on-top-software-products/ © 2024 Send2Press® Newswire, a press release distribution service, Calif., USA. Disclaimer: This press release content was not created by nor issued by the Associated Press (AP). Content below is unrelated to this news story.Article content DENVER — Amid renewed interest in the killing of JonBenet Ramsey triggered in part by a new Netflix documentary, police in Boulder, Colorado, refuted assertions this week that there is viable evidence and leads about the 1996 killing of the 6-year-old girl that they are not pursuing. Recommended Videos JonBenet Ramsey, who competed in beauty pageants, was found dead in the basement of her family’s home in the college town of Boulder the day after Christmas in 1996. Her body was found several hours after her mother called 911 to say her daughter was missing and a ransom note had been left behind. The details of the crime and video footage of JonBenet competing in pageants propelled the case into one of the highest-profile mysteries in the United States. The police comments came as part of their annual update on the investigation, a month before the 28th anniversary of JonBenet’s killing. Police said they released it a little earlier due to the increased attention on the case, apparently referring to the three-part Netflix series “ Cold Case: Who Killed JonBenet Ramsey .” In a video statement, Boulder Police Chief Steve Redfearn said the department welcomes news coverage and documentaries about the killing of JonBenet, who would have been 34 this year, as a way to generate possible new leads. He said the department is committed to solving the case but needs to be careful about what it shares about the investigation to protect a possible future prosecution. “What I can tell you though, is we have thoroughly investigated multiple people as suspects throughout the years and we continue to be open-minded about what occurred as we investigate the tips that come into detectives,” he said. As we approach the 28th anniversary of the murder of JonBenet Ramsey, the Boulder Police Department is providing its annual update about the ongoing homicide investigation. “The killing of JonBenet was an unspeakable crime and this tragedy has never left our hearts,” Boulder... pic.twitter.com/0qmZuwU6kO The Netflix documentary focuses on the mistakes made by police and the “media circus” surrounding the case. JonBenet was bludgeoned and strangled. Her death was ruled a homicide, but nobody was ever prosecuted. Police were widely criticized for mishandling the early investigation into her death amid speculation that her family was responsible. However, a prosecutor cleared her parents, John and Patsy Ramsey, and brother Burke in 2008 based on new DNA evidence from JonBenet’s clothing that pointed to the involvement of an “unexplained third party” in her slaying. The announcement by former district attorney Mary Lacy came two years after Patsy Ramsey died of cancer. Lacy called the Ramseys “victims of this crime.” John Ramsey has continued to speak out for the case to be solved. In 2022, he supported an online petition asking Colorado’s governor to intervene in the investigation by putting an outside agency in charge of DNA testing in the case. In the Netflix documentary, he said he has been advocating for several items that have not been prepared for DNA testing to be tested and for other items to be retested. He said the results should be put through a genealogy database. In recent years, investigators have identified suspects in unsolved cases by comparing DNA profiles from crime scenes and to DNA testing results shared online by people researching their family trees. In 2021, police said in their annual update that DNA hadn’t been ruled out to help solve the case, and in 2022 noted that some evidence could be “consumed” if DNA testing is done on it. Last year, police said they convened a panel of outside experts to review the investigation to give recommendations and determine if updated technologies or forensic testing might produce new leads. In the latest update, Redfearn said that review had ended but that police continue to work through and evaluate a “lengthy list of recommendations” from the panel. — Amy Beth Hanson contributed to this report from Helena, Montana.
Los Angeles Chargers (7-4) at Atlanta (6-5) Sunday, 1 p.m. EST, CBS BetMGM NFL Odds: Chargers by 1 1/2 Series record: Falcons lead 8-4. Against the spread: Chargers 7-3-1, Falcons 5-6. Last meeting: Chargers beat Falcons 20-17 on Nov. 6, 2022, in Atlanta. Last week: Ravens beat Chargers, 30-23; Falcons had bye week following 38-6 loss at Denver on Nov. 17. Chargers offense: overall (21), rush (13), pass (20), scoring (18). Chargers defense: overall (13), rush (10), pass (10), scoring (13). Falcons offense: overall (8), rush (14), pass (5), scoring (16). Falcons defense: overall (25), rush (19), pass (26), scoring (26). Turnover differential: Chargers plus-8, Falcons minus-3. Chargers player to watch RB Gus Edwards could move up as the lead back for Los Angeles as J.K Dobbins (knee) is expected to miss the game . Edwards was activated from injured reserve earlier this month following an ankle injury and had nine carries for 11 yards with a touchdown in Monday night's 30-23 loss to Baltimore. Falcons player to watch WR Drake London has 61 catches, leaving him four away from becoming the first player in team history to have at least 65 receptions in each of his first three seasons. London has 710 receiving yards, leaving him 140 away from becoming the first player in team history with at least 850 in each of his first three seasons. Key matchup Falcons RB Bijan Robinson vs. Chargers run defense. Robinson was shut down by Denver, gaining only 35 yards on 12 carries, and the Atlanta offense couldn't recover. The Chargers rank 10th in the league against the run, so it will be a challenge for the Falcons to find a way to establish a ground game with Robinson and Tyler Allgeier. A solid running attack would create an opportunity for offensive coordinator Zac Robinson to establish the play-action passes for quarterback Kirk Cousins. Key injuries Dobbins appeared to injure his right knee in the first half of the loss to the Ravens, though coach Jim Harbaugh did not provide details. ... The Falcons needed the bye to give a long list of injured players an opportunity to heal. WR WR KhaDarel Hodge (neck) did not practice on Wednesday. WR Darnell Mooney (Achilles), CB Kevin King (concussion), DL Zach Harrison (knee, Achilles) and WR Casey Washington (concussion) were hurt in the 38-6 loss at Denver on Nov. 17 and were limited on Wednesday. CB Mike Hughes (neck), nickel back Dee Alford (hamstring), ILB Troy Andersen (knee), TE Charlie Woerner (concussion) and ILB JD Bertrand (concussion) also were limited on Wednesday after not playing against Denver. C Drew Dalman (ankle) could return. Series notes The Chargers have won the past three games in the series following six consecutive wins by the Falcons from 1991-2012. Los Angeles took a 33-30 overtime win in Atlanta in 2016 before the Chargers added 20-17 wins at home in 2020 and in Atlanta in 2022. The Falcons won the first meeting between the teams, 41-0 in San Diego in 1973. Stats and stuff Each team has built its record on success against the soft NFC South. Atlanta is 4-1 against division rivals. Los Angeles is 2-0 against the NFC South this season. The Chargers have a four-game winning streak against the division. ... Atlanta is 0-2 against AFC West teams, following a 22-17 loss to Kansas City and the lopsided loss at Denver. They will complete their tour of the AFC West with a game at the Las Vegas Raiders on Dec. 16. ... The Falcons are the league's only first-place team with a negative points differential. Atlanta has been outscored 274-244. Fantasy tip The loss of Dobbins, who has rushed for eight touchdowns, could put more pressure on QB Justin Hebert and the passing game. Herbert's favorite option has been WR Ladd McConkey, who has four TD receptions among his 49 catches for 698 yards. McConkey, the former University of Georgia standout who was drafted in the second round, could enjoy a productive return to the state against a Falcons defense that ranks only 26th against the pass. AP NFL: https://apnews.com/hub/nfl
NoneGeneral Atlantic sells $119.25 million in Alkami Technology sharesThese are my favorite Find My accessories this holiday season